Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

α‐Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid—A Systematic Review and Meta‐Analysis
Anna Grossauer, Greta Hemicker, Florian Krismer, et al.
Movement Disorders Clinical Practice (2023) Vol. 10, Iss. 5, pp. 737-747
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Gill Livingston, Jonathan Huntley, Kathy Liu, et al.
The Lancet (2024) Vol. 404, Iss. 10452, pp. 572-628
Closed Access | Times Cited: 619
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Tanya Simuni, Lana M. Chahine, Kathleen L. Poston, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 2, pp. 178-190
Closed Access | Times Cited: 251
Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onset
Jenny Hällqvist, Michael Bartl, Mohammed Dakna, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 28
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Jeffrey L. Cummings, Charlotte E. Teunissen, Brian Fiske, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 2
Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions
Angeliki Zarkali, George E. Thomas, Henrik Zetterberg, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 16
α-Synuclein seed amplification technology for Parkinson’s disease and related synucleinopathies
Claudio Soto
Trends in biotechnology (2024) Vol. 42, Iss. 7, pp. 829-841
Closed Access | Times Cited: 10
Current trends in blood biomarkers detection and neuroimaging for Parkinson's disease
Ni Liu, Tianjiao Zhang, Wei Zhao, et al.
Ageing Research Reviews (2025), pp. 102658-102658
Closed Access | Times Cited: 1
PIDGN: An explainable multimodal deep learning framework for early prediction of Parkinson's disease
Wenjia Li, Qiu Rao, Shuying Dong, et al.
Journal of Neuroscience Methods (2025), pp. 110363-110363
Closed Access | Times Cited: 1
Toward a biological definition of neuronal and glial synucleinopathies
Claudio Soto, Brit Mollenhauer, Oskar Hansson, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Pre-symptomatic Parkinson’s disease blood test quantifying repetitive sequence motifs in transfer RNA fragments
Nimrod Madrer, Shani Vaknine, Tamara Zorbaz, et al.
Nature Aging (2025)
Open Access | Times Cited: 1
Biological effects of pathologies in Lewy body diseases: why timing matters
Elie Matar, Glenda M. Halliday
The Lancet Neurology (2025) Vol. 24, Iss. 5, pp. 441-455
Closed Access | Times Cited: 1
How should we be using biomarkers in trials of disease modification in Parkinson’s disease?
Nirosen Vijiaratnam, Thomas Foltynie
Brain (2023) Vol. 146, Iss. 12, pp. 4845-4869
Open Access | Times Cited: 21
Comparison of biospecimens for α‐synuclein seed amplification assays in Parkinson's disease: A systematic review and network meta‐analysis
Yuanchu Zheng, Siming Li, Yang Chen, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 12, pp. 3949-3967
Closed Access | Times Cited: 20
A systematic review of salivary biomarkers in Parkinson’s disease
M Bartolo, Daniele Belvisi, Romina Mancinelli, et al.
Neural Regeneration Research (2024) Vol. 19, Iss. 12, pp. 2613-2625
Open Access | Times Cited: 6
Limitations of the α-Synuclein Seed Amplification Assay in Clinical Practice
Huw R. Morris, Andrew Lees
JAMA Neurology (2024) Vol. 81, Iss. 9, pp. 905-905
Closed Access | Times Cited: 6
Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions
Félix Javier Jiménez‐Jiménez, Hortensia Alonso‐Navarro, Elena García‐Martín, et al.
Biomolecules (2023) Vol. 13, Iss. 8, pp. 1263-1263
Open Access | Times Cited: 16
α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders
Taku Hatano, Ayami Okuzumi, Gen Matsumoto, et al.
Journal of Movement Disorders (2024) Vol. 17, Iss. 2, pp. 127-137
Open Access | Times Cited: 6
Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease
Michael Bartl, Johanna Nilsson, Mohammed Dakna, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Biomarker‐Based Approach to α‐Synucleinopathies: Lessons from Neuropathology
Gábor G. Kovács, Lea T. Grinberg, Glenda M. Halliday, et al.
Movement Disorders (2024)
Open Access | Times Cited: 4
Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment
Florian Krismer, Alessandra Fanciulli, Wassilios G. Meissner, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 12, pp. 1252-1266
Closed Access | Times Cited: 4
α-Synuclein pathology as a target in neurodegenerative diseases
Hye-Jin Park, Tae‐In Kam, Valina L. Dawson, et al.
Nature Reviews Neurology (2024)
Closed Access | Times Cited: 4
Detection of alpha synuclein seeding activity in tear fluid in patients with Parkinson's disease
Sezgi Canaslan, Matthias Schmitz, Fabian Maass, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Atypical Parkinsonian Disorders
Nahid Olfati, Fahimeh Haji Akhoundi, Irene Litvan
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 249-277
Closed Access
Biomarkers in Parkinson’s Disease
Sarah M. Brooker, Paulina Gonzàlez‐Latapi
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 229-248
Closed Access
Disease-Modifying Therapies in Parkinson’s Disease
Margherita Fabbri, Jean‐Christophe Corvol, Olivier Rascol
Neurologic Clinics (2025) Vol. 43, Iss. 2, pp. 319-340
Closed Access
Page 1 - Next Page

Scroll to top